Biotech Bearish Stocks: Reliv International (NASDAQ:RELV), Ocera Therapeutics (NASDAQ:OCRX), MediciNova (NASDAQ:MNOV), PTC Therapeutics (NASDAQ:PTCT)

Registrant and three of its wholly-owned subsidiaries, Reliv, International, Inc (NASDAQ:RELV), Reliv World Corporation and SL Technology, Inc. entered into a Credit Agreement with BMO Harris Bank N.A. (the “Bank”) pursuant to which the Bank agreed to provide certain credit facilities to Registrant, including a Term Loan in the principal amount of $3,481,961 and a revolving credit facility in the amount of $5,000,000. Reliv International, Inc (NASDAQ:RELV) stock performance was -5.17% in last session and finished the day at $2.20. Traded volume was 26,978.00million shares in the last session and the average volume of the stock remained 15.85K shares. The beta of the stock remained 1.60. Reliv International, Inc (NASDAQ:RELV) insider ownership is 0.20%.

Ocera Therapeutics Inc (NASDAQ:OCRX) is a company with one main value driver, OCR002. Financially, the company is now sitting on $47.2 M and will be spending $30M in the 2014 financial year. Ocera Therapeutics Inc (NASDAQ:OCRX) dropped -5.04 percent to $10.56 Wednesday on volume of 84,085.00million shares. The intra-day range of the stock was $10.32 to $11.45. Ocera Therapeutics Inc (NASDAQ:OCRX) has a market capitalization of $163.19million.

On March 28, 2014 (Japanese Standard Time), MediciNova, Inc. (NASDAQ:MNOV) filed with the Tokyo Stock Exchange a Japanese report referred to as “Kessan Tanshin,” which contained the Company’s financial results for the year ended December 31, 2013 (the “Tanshin”). MediciNova, Inc. (NASDAQ:MNOV)’s stock on Apr 02, 2014 reported a decrease of -5.41% to the closing price of $2.10. Its fifty two weeks range is $1.91 -$5.25. The total market capitalization recorded $47.04million. The overall volume in the last trading session was 98,944.00million shares. In its share capital, MNOV has 24.08million outstanding shares.

PTC Therapeutics (NASDAQ:PTCT) CEO Stuart Walter Peltz sold 25,487 shares of the company’s stock on the open market in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $29.86, for a total value of $761,041.82. Following the sale, the chief executive officer now directly owns 135,902 shares of the company’s stock, valued at approximately $4,058,034. On Wednesday, shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) dropped -7.31% to close the day at $25.10. Company return on investment (ROI) is -33.30% and its monthly performance is recorded as -25.87%. PTC Therapeutics, Inc. (NASDAQ:PTCT) quarterly revenue growth is 47.91%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone